The Oncology Institute, Inc. Common Stock (TOI) Stock Price
TOIStock
$7.05+106.14%52W
Market Cap$704.88M
P/E—
PEG Ratio—
Div yield—
Beta-0.46
TOI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)78.91%
Price vs S&P 500 (4W)10.93%
VGM Score68.54
TOI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q1 2026 | -$0.09 | -$0.02 | +77.14%(+$0.07) | |
| Q4 2025 | -$0.09 | -$0.06 | +33.33%(+$0.03) | |
| Q3 2025 | -$0.11 | -$0.14 | -23.53%(-$0.03) | |
| Q2 2025 | -$0.12 | -$0.15 | -25.00%(-$0.03) |
TOI Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.13
4.11
Industry Peers — Physicians' Offices(15)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
TOIThe Oncology Institute, Inc. Common Stock | D | A | A | — | 35.4% | -6.0% | -482.6% | $7.05 |
| HIMSHims & Hers Health, Inc. | D | B | D | 51.0x | 28.0% | -6.0% | -30.0% | $28.07 |
| TDOCTeladoc Health, Inc. | A | C | D | — | -2.1% | -7.5% | -13.1% | $5.67 |
| STLNStarling Oncology, Inc. Common Stock | F | A | D | — | 38.4% | -4.4% | -482.6% | $6.43 |
| SBCSBC Medical Group Holdings Incorporated Common Stock | B | C | B | 10.4x | -6.9% | 37.3% | 19.3% | $5.16 |
| AUNAAuna S.A. | A | D | C | 13.9x | 7.8% | 13.4% | 0.9% | $5.32 |
| LFMDLifeMD, Inc. Common Stock | C | C | F | 7.9x | -16.7% | -12.4% | 1.7% | $2.34 |
| AIRSAirSculpt Technologies, Inc. Common Stock | C | F | F | — | -8.7% | -8.3% | -12.5% | $1.27 |
| WSTNWestin Acquisition Corp Class A Ordinary Share | — | — | C | — | — | — | — | $10.21 |
| CCMConcord Medical Services Holding Limited | B | A | D | — | 40.1% | -45.0% | -11.6% | $3.63 |
| BMGLBasel Medical Group Ltd Ordinary Shares | C | A | D | — | 29.8% | -55.9% | -178.8% | $3.95 |
About The Oncology Institute, Inc. Common Stock
The Oncology Institute Inc operates a diversified oncology platform providing infusion services, specialty pharmacy dispensing, stem cell transplants, clinical trials, and supportive care services. The company generates revenue primarily through its patient services segment, with additional contributions from its proprietary dispensary and clinical trials operations. Its integrated model spans diagnosis, treatment, research, and comprehensive patient support across the oncology care continuum.